Statistics for Ultragenyx Pharmaceutical (id:7470 RARE)

Valuation metrics

Market cap

4.04B

Enterprise value

4.44B

Trailing P/E (ttm)

-5.73

Forward P/E

-8.57

PEG ratio

-8.57

Price/Sales (ttm)

7.73

Price/Book (mrq)

11.64

Enterprise Value/Revenue

8.50

Enterprise Value/EBITDA

-8.86

Overview

Shares outstanding

92.34M

Float

89.01M

Shares short

3.18M

% Held by insiders

0.04%

% Held by institutions

0.98%

Average volume (10 days)

1.06M

Average volume (90 days)

Price summary

52-Week low

37.02

52-Week high

60.37

52-Week change

18.27%

Beta

0.58

50-Day moving average

54.25

200-Day moving average

48.10

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-106.93%

Operating margin

-94.62%

Operational effectiveness

Return on assets

-24.12%

Return on equity

-289.98%

Income statement

Revenue (ttm)

6.02

Revenue per share (ttm)

6.02

Quarterly revenue growth (yoy)

Gross profit (ttm)

389.04M

EBITDA

-501,062,016.00

Net income to common (ttm)

-558,988,032.00

Diluted EPS (ttm)

-6.35

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

607.51M

Total cash per share (mrq)

6.58

Total debt (mrq)

912.50M

Total Debt/Equity (mrq)

257.89

Current ratio (mrq)

280.60%

Book value per share (mrq)

3.76

Cash flow

Cash flow statement

-418,588,992.00

Levered free cash flow (LFCF)

-231,160,368.00